Your browser doesn't support javascript.
loading
Depletion of Conventional Type-1 Dendritic Cells in Established Tumors Suppresses Immunotherapy Efficacy.
Teijeira, Alvaro; Garasa, Saray; Luri-Rey, Carlos; de Andrea, Carlos; Gato, Maria; Molina, Carmen; Kaisho, Tsuneyasu; Cirella, Assunta; Azpilikueta, Arantza; Wculek, Steffanie K; Egea, Josune; Olivera, Irene; Rodriguez, Inmaculada; Rouzaut, Ana; Verkhusha, Vladislav; Valencia, Karmele; Sancho, David; Berraondo, Pedro; Melero, Ignacio.
Afiliação
  • Teijeira A; Immunology and Immunotherapy Department, Center for Applied Medical Research (CIMA), Universidad de Navarra, Pamplona, Spain.
  • Garasa S; Navarra Institute of Health Research (IDISNA), Pamplona, Spain.
  • Luri-Rey C; Centro de Investigación Biomédica en Red en Oncología (CIBERONC), Madrid, Spain.
  • de Andrea C; Immunology and Immunotherapy Department, Center for Applied Medical Research (CIMA), Universidad de Navarra, Pamplona, Spain.
  • Gato M; Navarra Institute of Health Research (IDISNA), Pamplona, Spain.
  • Molina C; Immunology and Immunotherapy Department, Center for Applied Medical Research (CIMA), Universidad de Navarra, Pamplona, Spain.
  • Kaisho T; Navarra Institute of Health Research (IDISNA), Pamplona, Spain.
  • Cirella A; Pathology Department, Clinica Universidad de Navarra, Pamplona, Spain.
  • Azpilikueta A; Immunology and Immunotherapy Department, Center for Applied Medical Research (CIMA), Universidad de Navarra, Pamplona, Spain.
  • Wculek SK; Immunology and Immunotherapy Department, Center for Applied Medical Research (CIMA), Universidad de Navarra, Pamplona, Spain.
  • Egea J; Department of Immunology, Institute of Advanced Medicine, Wakayama Medical University, Wakayama, Japan.
  • Olivera I; Immunology and Immunotherapy Department, Center for Applied Medical Research (CIMA), Universidad de Navarra, Pamplona, Spain.
  • Rodriguez I; Immunology and Immunotherapy Department, Center for Applied Medical Research (CIMA), Universidad de Navarra, Pamplona, Spain.
  • Rouzaut A; Navarra Institute of Health Research (IDISNA), Pamplona, Spain.
  • Verkhusha V; Centro de Investigación Biomédica en Red en Oncología (CIBERONC), Madrid, Spain.
  • Valencia K; Immunobiology Lab, Centro Nacional de Investigación Cardiovasculares (CNIC), Madrid, Spain.
  • Sancho D; Immunology and Immunotherapy Department, Center for Applied Medical Research (CIMA), Universidad de Navarra, Pamplona, Spain.
  • Berraondo P; Immunology and Immunotherapy Department, Center for Applied Medical Research (CIMA), Universidad de Navarra, Pamplona, Spain.
  • Melero I; Immunology and Immunotherapy Department, Center for Applied Medical Research (CIMA), Universidad de Navarra, Pamplona, Spain.
Cancer Res ; 82(23): 4373-4385, 2022 12 02.
Article em En | MEDLINE | ID: mdl-36130020
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Toxina Diftérica / Neoplasias Hepáticas Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Cancer Res Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Espanha
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Toxina Diftérica / Neoplasias Hepáticas Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Cancer Res Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Espanha